MRI and laboratory monitoring of disease-modifying therapy efficacy and risks

Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies

(2022) Luca Prosperini et al.   JOURNAL OF NEUROLOGY

Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis

(2022) Benjamin V. Ineichen et al.   NeuroImage-Clinical

Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function

(2022) Joseph J. Sabatino et al.   JCI Insight

Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis

(2021) Samuel Klistorner et al.   PLoS One

Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment

(2021) Riccardo Garbo et al.   Multiple Sclerosis and Related Disorders

MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a

(2021) Maria P. Sormani et al.   Multiple Sclerosis and Related Disorders

Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging

(2021) Reza Rahmanzadeh et al.   BRAIN

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

(2021) Tal Brosh-Nissimov et al.   CLINICAL MICROBIOLOGY AND INFECTION

Chronic active lesions: a new MRI biomarker to monitor treatment effect in multiple sclerosis?

(2021) Paolo Preziosa et al.   Expert Review of Neurotherapeutics

Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy

(2021) Chenyu Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

(2021) Stephen L Hauser et al.   NEUROLOGY

COVID ‐19 Vaccine Response in People with Multiple Sclerosis

(2021) Emma C. Tallantyre et al.   ANNALS OF NEUROLOGY

The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective

(2021) Laura E Baldassari et al.   BRAIN

DeepLesionBrain: Towards a broader deep-learning generalization for multiple sclerosis lesion segmentation

(2021) Reda Abdellah Kamraoui et al.   MEDICAL IMAGE ANALYSIS

The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK

(2021) Linford Fernandes et al.   Multiple Sclerosis and Related Disorders

Measuring treatment response to advance precision medicine for multiple sclerosis

(2021) Peter A. Calabresi et al.   Annals of Clinical and Translational Neurology

Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis

(2020) Russell Ouellette et al.   ANNALS OF NEUROLOGY

Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis

(2020) Luca Prosperini et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions

(2020) Jean-Christophe Brisset et al.   JOURNAL OF NEURORADIOLOGY

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

(2020) Bénédicte Delcoigne et al.   NEUROLOGY

Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis

(2020) Mahtab Ghadiri et al.   Scientific Reports

Sensitivity of the Inhomogeneous Magnetization Transfer Imaging Technique to Spinal Cord Damage in Multiple Sclerosis

(2020) H. Rasoanandrianina et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population

(2020) Giacomo Boffa et al.   CNS DRUGS

COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases

(2020) D. Baker et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature

(2020) Catharina Korsukewitz et al.   Nature Reviews Neurology

Neurofilament light as a biomarker in traumatic brain injury

(2020) Pashtun Shahim et al.   NEUROLOGY

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serious safety events in rituximab‐treated multiple sclerosis and related disorders

(2020) Brandi L. Vollmer et al.   Annals of Clinical and Translational Neurology

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

(2020) Stefan Bittner et al.   EBioMedicine

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

(2020) David Baker et al.   Multiple Sclerosis and Related Disorders

Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI

(2020) Assunta Dal-Bianco et al.   BRAIN

Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients

(2020) Samuel Klistorner et al.   Multiple Sclerosis Journal

Chitinases and chitinase-like proteins as biomarkers in neurologic disorders

(2020) Rucsanda Pinteac et al.   Neurology-Neuroimmunology & Neuroinflammation

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

(2019) J. William L. Brown et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

(2019) Katharine Harding et al.   JAMA Neurology

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate

(2019) Cristina Scarpazza et al.   Multiple Sclerosis Journal

Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis

(2019) Michael G. Dwyer et al.   JOURNAL OF NEUROIMAGING

Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS

(2019) Chenyu Wang et al.   Neurology-Neuroimmunology & Neuroinflammation

The association between lymphopenia and serious infection risk in rheumatoid arthritis

(2019) Sujith Subesinghe et al.   RHEUMATOLOGY

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

(2019) Ester Cantó et al.   JAMA Neurology

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

(2018) Bibiana Quirant-Sánchez et al.   CNS Neuroscience & Therapeutics

Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL

(2018) Roland Opfer et al.   JOURNAL OF NEUROLOGY

Prediction of natalizumab anti-drug antibodies persistency

(2018) Florian Deisenhammer et al.   Multiple Sclerosis Journal

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study

(2018) Stephen W Reddel et al.   Multiple Sclerosis Journal

Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials

(2018) CH Brahe et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Prediction of natalizumab anti-drug antibodies persistency

(2018) Florian Deisenhammer et al.   Multiple Sclerosis Journal

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study

(2018) Stephen W Reddel et al.   Multiple Sclerosis Journal

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

(2018) Yara Dadalti Fragoso et al.   Multiple Sclerosis and Related Disorders

The evolution of “No Evidence of Disease Activity” in multiple sclerosis

(2018) G. Lu et al.   Multiple Sclerosis and Related Disorders

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

(2018) Colm Elliott et al.   Multiple Sclerosis Journal

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

(2017) Pei-Ran Ho et al.   LANCET NEUROLOGY

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

(2017) Vinzenz Fleischer et al.   Multiple Sclerosis Journal

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

(2017) Vinzenz Fleischer et al.   Multiple Sclerosis Journal

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

(2016) Douglas L. Arnold et al.   NEUROLOGY

Identification of tissue-specific cell death using methylation patterns of circulating DNA

(2016) Roni Lehmann-Werman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients

(2014) M. M. Gresle et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Managing the risks of immunosuppression

(2011) D Sean Riminton et al.   CURRENT OPINION IN NEUROLOGY

Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study

(2010) R. Takano et al.   NEUROLOGY